THE BELLY FAT MELTER

Tesamorelin

Grade BGood

FDA-approved GHRH analog that melts visceral fat

Also known as: GHRH(1-44) Analog; Egrifta

Hormonal Regulation
Anti-Aging & Longevity
Weight Management

Overview

Tesamorelin is an FDA-approved GHRH analog originally developed for HIV-associated lipodystrophy. It stimulates your pituitary to release growth hormone in natural patterns, which then increases IGF-1. It's particularly effective at reducing visceral (belly) fat and improving body composition. It also shows cognitive benefits in some studies.

Key Benefits & Mechanisms

GHRH Receptor Activation

Binds pituitary GHRH receptors to stimulate GH release

IGF-1 Elevation

Increases hepatic IGF-1 production

Lipolysis

Promotes visceral fat breakdown

Cognitive Support

May improve memory through GH/IGF-1 effects

Dosing Guide

Dosage

2 mg subcutaneously once daily (evening)

Schedule

daily

Cycle

3-6 months on, then as prescribed

Pro Tip

Inject in the evening; prescription required in most countries

Safety Profile

B

Good Safety

Good

FDA-approved with well-characterized side effects.

Avoid in active cancer or uncontrolled diabetes. May affect glucose.

Possible Side Effects

Injection site reactions
Joint pain
Edema
Nausea
Sleep disturbance

What to Expect

Week 2-4

Increased GH and IGF-1 levels

Month 1-2

Improved energy and body composition starting

Month 3-6

Significant visceral fat reduction

Visceral fat reduction typically visible within 3 months.

Who Is This For

Those with excess visceral fat
People with HIV-associated lipodystrophy
Those wanting FDA-approved GH therapy
Anyone seeking improved body composition
People interested in cognitive benefits of GH

Research References

Related Peptides

Ready to Start Your Peptide Journey?

Track your protocols, get guided reconstitution, and access our vetted vendor network — all in one app.

Download The Peptide App